1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
Year: 2020
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Banner MD Anderson Cancer Center, The University of Sydney, Blacktown & Mount Druitt Hospital, The Alfred Hospital, Alfred Health, Monash University, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Asan Medical Center, Samsung Medical Center, Tennessee Oncology, University of Colorado Cancer Center, University of Colorado Anschutz, City Of Hope National Medical Center, Levine Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), Rambam Health Care Campus
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Merck Sharp and Dohme
OpenAlex ID: W3088018189